Cyltezo Purple Book BLA 761058

BLA number
761058
Proprietary names
Cyltezo
Proper names
adalimumab-adbm
Applicant
Boehringer Ingelheim Pharmaceuticals, Inc.
Center
CDER
First observed release
2020-02-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Cyltezoadalimumab-adbm351(k) Interchangeable40MG/0.8MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2017-08-25
002Cyltezoadalimumab-adbm351(k) Interchangeable20MG/0.4MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2018-07-13
003Cyltezoadalimumab-adbm351(k) Interchangeable10MG/0.2MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2022-03-18
004Cyltezoadalimumab-adbm351(k) Interchangeable40MG/0.8MLInjectionSubcutaneousAutoinjectorRxLicensed2023-05-18
005Cyltezoadalimumab-adbm351(k) Interchangeable40MG/0.4MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2024-04-30
006Cyltezoadalimumab-adbm351(k) Interchangeable40MG/0.4MLInjectionSubcutaneousAutoinjectorRxLicensed2024-04-30

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125057Humiraadalimumab351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-05-01U005Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2025-05-01U006Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2024-05-01N005Cyltezo351(k) BiosimilarRxBoehringer Ingelheim Pharmaceuticals, Inc.
2024-05-01N006Cyltezo351(k) BiosimilarRxBoehringer Ingelheim Pharmaceuticals, Inc.
2023-10-01U001Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2023-10-01U002Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2023-10-01U003Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2023-10-01U004Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2023-06-01U004Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2022-05-01U003Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2021-10-01U001Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.
2021-10-01U002Cyltezo351(k) InterchangeableRxBoehringer Ingelheim Pharmaceuticals, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-05-01005Cyltezo351(k) InterchangeableRxLicensed2024-04-30
2025-05-01006Cyltezo351(k) InterchangeableRxLicensed2024-04-30
2024-05-01005Cyltezo351(k) BiosimilarRxLicensed2024-04-30
2024-05-01006Cyltezo351(k) BiosimilarRxLicensed2024-04-30
2023-06-01004Cyltezo351(k) InterchangeableRxLicensed2023-05-18
2022-05-01003Cyltezo351(k) InterchangeableRxLicensed2022-03-18
2021-10-01001Cyltezo351(k) InterchangeableRxLicensed2017-08-25
2021-10-01002Cyltezo351(k) InterchangeableRxLicensed2018-07-13
2020-05-01001Cyltezo351(k) BiosimilarRxLicensed2017-08-25
2020-05-01002Cyltezo351(k) BiosimilarRxLicensed2018-07-13
2020-02-01001Cyltezo351(k) BiosimilarMarketedLicensed2017-08-25
2020-02-01002Cyltezo351(k) BiosimilarMarketedLicensed2018-07-13